# A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants

> **NCT02770521** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 23 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Treprostinil
- **DRUG:** Placebo
- **DRUG:** LY900014
- **DRUG:** Insulin Lispro

## Key facts

- **NCT ID:** NCT02770521
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2020-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02770521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02770521, "A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02770521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*